Biotech Values

[DewDiligence]

RVNC—I don’t consider EOLS to be serious competition for RVNC’s RT002. What EOLS hopes to sell in the US aesthetics market (if they can fix the manufacturing problems) is the same Botox-like product that EOLS’ provider, Daewoong, sells in Korea.

EOLS does not even claim their toxin is differentiated from Botox; rather, they contend that what sets them apart is their business model of becoming financial partners with injectors.

In the aesthetics arena, various companies (e.g. those who sell lasers) have tried the business model EOLS is pursuing—without much success. The problem with this business model is the obvious conflict of interest for the injectors.

p.s. EOLS has no intention whatsoever of participating in the therapeutic side of the US botulinum-toxin market.